BOSTON and NOIDA, India, Feb. 27, 2024 /PRNewswire/ -- Curadev, a drug discovery and development company, announced today a significant milestone in its development of drugs targeting the immune system to treat cancer. The dosing of patients with advanced sarcoma and Merkel cell carcinoma by intravenous infusion of Curadev's systemic allosteric STING agonist, CRD3874-SI, has been initiated in a Phase 1a/b dose escalation and expansion clinical trial (NCT06021626) currently underway at Memorial Sloan Kettering Cancer Center (MSKCC) in New York. The first 4-week treatment cycle for the first patient is complete without adverse events. The primary objective for the dose escalation is to evaluate the safety and tolerability of CRD3874-SI and to establish the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D).
BOSTON and NOIDA, India, Feb. 15, 2024 /PRNewswire/ -- Curadev is excited to introduce CRD3874, a first-in-class allosteric small molecule STING agonist, with distinct pharmacological properties that distinguish it from agents that bind to STING's cGAMP site. An intravenous formulation of this lead asset (CRD3874-SI) recently received approval from the US FDA for use in first-in-human studies in patients with advanced solid cancers.
SANDWICH, England, June 9, 2021 /PRNewswire/ -- Sulphobutyl ether ?-cyclodextrin (SBE-?-CD) is used as an excipient to improve the solubility and stability of a range of active pharmaceutical ingredients, prominent among which is the antifungal drug, voriconazole. Working with Professor Steve Wicks and his team at the University of Greenwich, Curadev developed a new method for producing sulphoalkyl ether ?-cyclodextrins. The method also enabled the production of SBE-?-CD with a high average degree of substitution (ADS), something which was not previously possible. This is particularly advantageous as it is thought that increasing the ADS of SBE-?-CD will decrease its toxicity. Curadev applied for and were granted a European patent on 18 April 2018 which protected both the method of producing SBE-?-CD and the novel SBE-?-CD compositions per se having a high (ADS).
Sulphobutylether-?-cyclodextrin (SBE-?-CD) is used as an adjuvant to improve the solubility and stability of a number of active pharmaceutical ingredients, including the antifungal agent voriconazole. In collaboration with Professor Steve Wicks and his team at the University of Greenwich, Curadev developed a new method for the production of sulfoalkyl ether-?-cyclodextrins. The method also enabled the production of SBE-?-CD with a high average degree of substitution (ADS), which was previously not possible. This is particularly beneficial as it is believed that increasing the ADD of SBE-?-CD will decrease its toxicity. Curadev applied for and received on April 18 , 2018a European patent protecting both the process for the preparation of SBE-?-CD and the novel SBE-?-CD compositions per se with a high (ADS).